Elanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) EV/FCF
As of 5 November 2026, Elanco Animal Health Incorporated (ELAN) trades at a EV/FCF of 42.7×. Over the past ten years it has ranged from −1,607× (November 2021) to 1,038× (December 2019); the current reading is higher than 61% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 56.1× | 112.29% |
| FY2024 | 26.4× | (75.51%) |
| FY2023 | 108× | 151.08% |
| FY2022 | 43.0× | (36.97%) |
| FY2021 | 68.2× | — |
| FY2020 | −68.4× | — |
| FY2019 | −218× | — |
| FY2018 | 32.3× | (24.76%) |
| FY2017 | 42.9× | 0.00% |
| FY2016 | 42.9× | 0.00% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 43.9× | (16.83%) |
| Mar 2026 | 52.8× | (5.91%) |
| Dec 2025 | 56.1× | 43.59% |
| Sep 2025 | 39.1× | 23.13% |
| 31 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −158× |
| NBIX Neurocrine Biosciences, Inc. compare | 15.5× |
| VTRS Viatris Inc. compare | 16.3× |
| LNTH Lantheus Holdings, Inc. compare | 16.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 32.2× |
| ALKS Alkermes plc compare | 36.0× |
| ELAN Elanco Animal Health Incorporated | 42.7× |
| HIMS Hims & Hers Health, Inc. compare | 73.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ELAN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement